All In Biotech

Drug Trial Radar · NCT06066125

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

351

Actual

Start

Mar 31, 2023

Primary completion

Aug 19, 2024

Study completion Aug 19, 2024

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Oct 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis
  • Skin Diseases

Interventions

  • AK111Drug

    AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

  • AK111Drug

    AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

  • PlaceboDrug

    Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects who achieved at least 75% reduction in psoriasis area and severity index(PASI) score from baseline (PASI 75) and the percentage of subjects who achieved static physician global assessment(sPGA) 0/1 at week 12.Time frame: at week 12

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing friendship hospital, Capital Medical University

    Beijing, China

  • Peking University third hospital

    Beijing, China

  • Guangdong provincial people's hospital

    Guangdong, China

  • Affiliated hospital of Chengde Medical University

    Hebei, China

  • The second affiliated hospital of Harbin Medical University

    Heilongjiang, China

  • Xiangya hospital Central South University

    Hunan, China

  • Huashan hospital, Fudan University

    Shanghai, China

  • Shanghai skin disease hospital

    Shanghai, China

  • The first affiliated hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The first affiliated hospital of wannan medical college

    Wannan, Anhui, China

  • Affiliated hospital of Chongqing Three Gorges Medical College

    Chongqing, Chongqing Municipality, China

  • Chongqing traditional Chinese medicine hospital (Daomenkou branch)

    Chongqing, Chongqing Municipality, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Shenzhen People's hospital

    Shenzhen, Guangdong, China

  • The first affiliated hospital of Hainan Medical university

    Haikou, Hainan, China

  • Nanyang First People's hospital national third class a hospital

    Nanyang, Henan, China

  • Renmin hospital of Wuhan University Hubei general hospital

    Wuhan, Hubei, China

  • Yichang central People's hospital

    Yichang, Hubei, China

  • The third Xiangya hospital of Central South University

    Changsha, Hunan, China

  • The frist People's hospital of Lianyungang

    Lianyungang, Jiangsu, China

  • Dermatology Hospital of China Union Medical University

    Nanjing, Jiangsu, China

  • The affiliated hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Yancheng No.1 People's hospital

    Yancheng, Jiangsu, China

  • Dermatology hospital of Jiangxi province

    Nanchang, Jiangxi, China

  • The second hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Second hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Tangdu hospital of the Fourth Military Medical University

    Tanggu, Shanxi, China

  • West China school of medicine, West China hospital of Sichuan University

    Chengdu, Sichuan, China

  • Tianjin academy of traditional Chinese medicine affiliated hospita

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University general hospital

    Tianjin, Tianjin Municipality, China

  • Hangzhou first People's hospital

    Hangzhou, Zhejiang, China

  • The first hospital of Jiaxing

    Jiaxing, Zhejiang, China

  • Ningbo Huamei hospital, University of Chinese Academy of Sciences

    Ningbo, Zhejiang, China

  • The first affiliated hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.